Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
Purpose of Study
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
Eligibility
Age:
35 - 55Sex:
FemaleAccepting Volunteers:
YES
Conditions:
Status:
RECRUITING
Phase:
Array
Clinical Trials ID
NCT06673069
Read Detailed Summary:
Start Date / End Date:
01 2025 - 02 2027
Enrollment:
30